In Vitro Endocrine Disruption Assay Services | LifeNet Health LifeSciences

In Vitro Endocrine Disruption Assays

Accurately evaluate potential disruption of the endocrine system, including thyroid hormone disruption, with our comprehensive assay portfolio.

Expedite drug development with reliable, human-relevant results from our dermal and ocular safety assays.

EXPLORE OUR ASSAYS

Featured assays

Thyroid Hormone Disruption - Indirect (T4 Glucuronidation)

Advance thyroid hormone disruption research with our innovative human 3D thyrocyte model, developed in collaboration with the U.S. Environmental Protection Agency. Designed to replicate native thyroid structure and function, this human-relevant model enables longer-term studies and comprehensive assessment of key thyroid endpoints—including T3, T4, TG, TPO activity, and TSHR agonism/antagonism. Integration with our microphysiological system platform also supports evaluation of thyroid-liver interactions associated with metabolic disruption and thyroid-related pathologies.

LEARN MORE

Thyroid Hormone Disruption - Direct (3D Thyroid microtissue model)

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris tincidunt risus quis neque ornare varius. Aliquam vel est eu dolor placerat sodales et ac nulla. Integer scelerisque mollis euismod. Sed ultrices nibh nec velit accumsan, non dictum lacus tempor. Sed dolor mauris, convallis ut accumsan vel, porta nec dolor. Sed vel lorem porttitor, lacinia metus feugiat, faucibus mi.

Cras metus erat, vestibulum non mi mattis, cursus imperdiet turpis. Sed scelerisque iaculis ligula. In est odio, lacinia sed mollis sit amet, feugiat sed nisl. Nunc a auctor lectus, nec blandit eros. Integer.

LEARN MORE

H295R Steroidogenesis Assay (OECD 456) with a Comprehensive 13 Steroid Panel

Steroidogenesis is a complex highly regulated pathway that begins with cholesterol and ends with the formation of estradiol and testosterone. This assay allows for the testing of chemicals that may disrupt the production of estrogen (E2) and testosterone (T). LifeNet Health LifeSciences follows OECD 456 test guidelines, using H295R cells to measure changes in the production of E2 and T following administration of a test chemical. A comprehensive 13 steroid panel is also available.

LEARN MORE

Common Assays We Offer

Endocrine Disruption Assays

We offer a complete suite of assays to evaluate potential disruption of the endocrine system, including our 3D Thyroid Microtissue model for thyroid disrupting chemicals (TDCs). Analyzing potential disruptions in vitro ensures accurate prediction of the effects of compounds on the endocrine system of target species in vivo. Our team of expert scientists can help in identifying the relevant endpoints to measure and the appropriate cells and culture conditions to accurately determine effects on the endocrine system.

Chemicals that disrupt thyroid function can act indirectly by affecting how thyroid hormones are metabolized by the liver. LifeNet Health's TruVivo 2D+ hepatic system provides both rat and human species options to enable cross-species translation to assess if an adverse event in the rat may or may not have relevance to human safety.

VIEW PRODUCT SHEET

LifeNet Health has developed a fully functional 3D thyroid microtissue model in collaboration with the US Environmental Protection Agency (EPA). This is the first human primary thyrocyte model that maintains T4 synthesis and thyroglobulin (TG) production for several days, enabling longer-term studies.

VIEW PRODUCT SHEET

The potential for a compound or chemical to affect steroidogenesis can be assessed early in the product development cycle to determine their relative risks for causing endocrine disruption. LifeNet Health LifeSciences offers the validated Steroidogenesis assay under OECD Test Guideline 456 for the assessment of potential induction, or inhibition, of steroidogenesis by test compounds or chemicals.

VIEW PRODUCT SHEET

The potential for a compound or chemical to bind to the estrogen receptor can be assessed early in the product development cycle to determine their relative risks for causing endocrine disruption. In our Estrogen Receptor Binding Assay, the PolarScreen™ ER Alpha Competitor Assay is used.

VIEW PRODUCT SHEET

LifeNet Health LifeSciences offers the validated ERTA assay for the assessment of potential estrogenic activation of test compounds or chemicals, operating in full compliance with the OECD 455 guideline.

VIEW PRODUCT SHEET

LifeNet Health LifeSciences offers the AR binding assay for the assessment of potential interference in the normal androgen hormone pathway. The AR binding assay provides mechanistic insight rapidly, which can be used for screening and prioritization purposes

VIEW PRODUCT SHEET

LifeNet Health LifeSciences offers the ARTA assay for the assessment of potential androgenic activation of test compounds or chemicals

VIEW PRODUCT SHEET

LifeNet Health LifeSciences offers the Aromatase assay for the assessment of potential interference of aromatase activity by test compounds or chemicals

VIEW PRODUCT SHEET

GET STARTED

Why partner with LifeNet Health® LifeSciences for your endocrine disruption studies?

Our experienced team is committed to helping you identify and customize endocrine disruption assays that accurately assess your drug candidate using methods based on current regulatory guidelines.

Our expansive services portfolio includes standardized methods as well as advanced methodologies only available to our partners. Our ability to utilize directly sourced, high-quality tissues, cells, and cell models sets us apart, enabling assay results that more accurately reflect human biology.

Our assay services team is committed to providing high quality data with timely turnaround for research and regulatory submission requirements.

CONSULT WITH AN EXPERT

Custom services and planning support

Offers GLP and non-GLP studies

New advanced methodologies

Expert regulatory

guidance

US Food and Drug Administration (FDA)

Environmental Protection Agency (EPA)

Health Canada

European Food Safety Association

European Medicines Agency (EMA)

Identifying thyroid disrupting drugs or chemicals with an innovative human 3D thyroid microtissue model

We are pleased to provide assessments of thyroid hormone disruption using an innovative human 3D thyrocyte model developed in collaboration with the US EPA. The thyrocytes recapitulate the structure and function of the thyroid gland when they form a 3D microtissue. The cells respond to the administration of thyroid stimulating hormone (TSH) by releasing T4. The cells in culture remain viable for several days which enables longer-term studies. Endpoints for this model include secretion of thyroxine (T4), thyroglobulin (TG), triiodothyronine (T3), thyroperoxidase activity (TPO), and TSHR agonism and antagonism.

The cells can be used in our microphysiological system platform to include thyroid-hormone events associated with liver metabolism which may lead to pathologies such as goiter and thyroid tumors.

DOWNLOAD OUR POSTER

3D Primary Human Thyroid Microtissues: An In Vitro Model for Studying Thyroid Hormone Disruption

VIEW OUR POSTER

T4 synthesis as dose response curves along with the respective IC50 values for each of the compound treatments with small compound methimazole and KPF6 (100 – 0.0001 μM) and TSHR antibody K1-70 (0.67 – 6.67x10-7 μM). Data was normalized to vehicle controls (0 μM).

VIEW OUR POSTER